Design and Evaluation of Polyox and Pluronic Controlled Gastroretentive Delivery of Troxipide

Objective. Objective of the present work was to develop site-specific gastroretentive drug delivery of Troxipide using polymers Pluronic F127 and Polyox 205 WSR. Troxipide is a novel gastroprotective agent with antiulcer, anti-inflammatory, and mucus secreting properties with elimination half-life o...

Full description

Saved in:
Bibliographic Details
Published inJournal of Drug Delivery Vol. 2014; no. 2014; pp. 176 - 185
Main Authors Jagdale, Swati C., Kamble, Shraddha B., Kuchekar, Bhanudas S., Chabukswar, Aniruddha R.
Format Journal Article
LanguageEnglish
Published Egypt Hindawi Limiteds 01.01.2014
Hindawi Publishing Corporation
Hindawi Limited
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective. Objective of the present work was to develop site-specific gastroretentive drug delivery of Troxipide using polymers Pluronic F127 and Polyox 205 WSR. Troxipide is a novel gastroprotective agent with antiulcer, anti-inflammatory, and mucus secreting properties with elimination half-life of 7.4 hrs. Troxipide inhibits H. pylori-derived urease. It is mainly absorbed from stomach. Methods. 32 factorial design was applied to study the effect of independent variable. Effects of concentration of polymer on dependant variables as swelling index, hardness, and % drug release were studied. Pluronic F127 and Polyox 205 WSR were used as rate controlled polymer. Sodium bicarbonate and citric acid were used as effervescent-generating agent. Results. From the factorial batches, it was observed that formulation F5 (19% Pluronic F127 and 80% Polyox 205 WSR) showed optimum controlled drug release (98.60% ± 1.82) for 10 hrs with ability to float >12 hrs. Optimized formulation characterized by FTIR and DSC studies confirmed no chemical interactions between drug and polymer. Gastroretention for 6 hrs for optimized formulations was confirmed by in vivo X-ray placebo study. Conclusion. Results demonstrated feasibility of Troxipide in the development of gastroretentive site-specific drug delivery.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Academic Editor: Jaleh Varshosaz
ISSN:2090-3014
2090-3022
DOI:10.1155/2014/804616